Optimised second-line regimens in the public health approach
- 27 August 2025
- journal article
- Published by Elsevier in The Lancet HIV
- Vol. 12 (9) , e604-e605
Abstract
No abstract availableFunding Information
- National University of Singapore
This publication has 7 references indexed in Scilit:
- Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trialThe Lancet HIV, 2025
- Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug ResistanceClinical Infectious Diseases, 2025
- Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trialThe Lancet HIV, 2024
- Second-Line Switch to Dolutegravir for Treatment of HIV InfectionNew England Journal of Medicine, 2023
- Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trialThe Lancet HIV, 2022
- Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trialThe Lancet Infectious Diseases, 2019
- Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trialThe Lancet HIV, 2017